Mahdi is a Scientist at Avro, he works in our R&D team to design and develop novel formulations and methods. He holds a PhD in Chemical Engineering from McGill. Previously, he has led projects on development of microdevices for monitoring heart-failure and delivering drugs through the skin as a postdoctoral fellow at the University of Montreal. Mahdi has authored 7 peer-reviewed articles on various subjects in physical chemistry, drug-delivery and nanoscience.
Joseph is a Senior Scientist at Avro, and leads our pipeline development, IP strategy, and regulatory strategy. He holds an MSc. and PhD in Pharmaceutical Sciences from the University of Toronto, where he developed and patented multifunctional organic building blocks for nanoparticles. He has published 3 first author papers in high impact factor journals, and previously served as a pharmaceutical consultant.
Samantha is a Scientist at Avro, and leads the development of our future formulation platforms. She holds a BSc in Biomedical Science and is completing her PhD in Pharmacy from the University of Waterloo, where she focused on the optimization of self-assembled gene delivery nanoparticles. Samantha has 3 peer-reviewed publications, and 2 book chapters on nanomedicine for gene therapy.
Shirley is a Research Associate at Avro, and works on our analytical chemistry team, turning the samples from our diffusion testing into actionable data and results. Shirley holds a BSc in Biochemistry from the University of Waterloo, and has years of experience in chemical product development and topical/semi-solid formulation testing in academic and GMP labs at the University of Waterloo and Septodont.
Drew is a Research Associate at Avro, and works on our formulation development and analytical chemistry teams. He holds a MEng in Chemical Engineering from the University of Waterloo, and spent 5 years working in the Gu Lab, developing nanostructured hydrogels for controlled release of agrochemicals. He holds 2 first author publications and 1 patent on his work, and has presented his research on bioencapsulation methodologies and more at conferences across Canada.
Andrew is a Research Associate at Avro, and works on our formulation development and diffusion testing teams. He holds a MEng in Biomedical Engineering from Ryerson University and a BASc in Nanotechnology Engineering from the University of Waterloo. He holds 3 publications in peer reviewed journals, and previously served as part of the early team at Qidni Labs, an early-stage materials science startup developing artificial kidneys.
Frank is VP of R&D at Avro, and leads our in-house method development, R&D into extended release, and commercialization/scaleup of our polymers. He holds an MD-PhD from McMaster University and the Ross School of Medicine. He previously served as the lead scientist and inventor for Interface Biologics, a leading Canadian drug-eluting polymer company. Frank has authored 11 peer-reviewed publications, and 6 patents.
Keean is the COO of Avro Life Science and oversees strategy, finance, and intellectual property at Avro. He was 1 of 25 students accepted to UWaterloo's prestigious accelerated PharmD program, and has years of experience working in healthcare, spanning clinical hospital pharmacy to community practice. Sarani previously engaged in epidemiology research at the SickKids Research Institute. Keean is an alumnus of Y-Combinator (W18), the Creative Destruction Lab and the Bayer Grants4Apps program.
Shak is the CEO of Avro Life Science. He studied nanotechnology engineering at the University of Waterloo, and previously published his research on biomaterial-based devices for personal cancer treatment at the University of Toronto. He went on to work under Frank Gu, the Canada Research Chair in controlled drug delivery, and now leads business development and day to day operations. Lakhani is an alumnus of Y-Combinator, the Creative Destruction Lab and the Bayer Grants4Apps program, and was named one of 20 Thiel Fellows in 2018.
Mays is a Scientist at Avro, working on the design and development of our novel cutaneous drug and gene delivery platforms. She obtained her Ph.D in Pharmaceutical Sciences from the University of Saskatchewan and completed a Postdoctoral Fellowship in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Mays is the author of 7 peer-reviewed research articles, a methodology book chapter and 40 poster & oral presentations. Her research findings were acclaimed by the scientific community, including awarding her the prestigious AAPS Award in Drug Discovery and Development. Mays is currently serving as the Chair of the American Association of Pharmaceutical Scientist Lipid-Based Drug Delivery Systems Community
Leo is a Scientist at Avro, and contributes to the development of our dermal delivery platform for multiple new modalities. He holds a PhD in Pathology from Western University, where he focused on siRNA delivery including liposome and polymer functionalized carbon nanotubes. Leo has 8 peer-reviewed publications, and 1 book chapter on siRNA delivery methods. Leo’s thesis work focused on siRNAs for the treatment of melanoma, and was validated in functional disease models.
Dr. Chris Cow is a senior chemist at Avro, tasked with designing novel ionic liquidsas vehicles for transdermal and topical drug delivery. Chris has an extensivebackground in the biotech and pharmaceutical industry, including 14 years as aresearch scientist at GNF (Novartis) in San Diego, where he developed structure-activity relationships on a variety of early drug discovery programs in areasincluding diabetes, cancer, and immune suppression. While there, he helpedadvance several of these projects to preclinical stages with at least one advancinginto human clinical trials. Prior to this, Chris also worked for Biovectra DCL in PrinceEdward Island, a custom chemistry company that specialized in medium to largescale synthesis under cGMP conditions. Chris obtained his Ph.D. in organicchemistry from McMaster University and went on to a postdoc at the University ofManitoba before embarking on his career in industry, and is a co-author on a dozenscientific papers and 19 patents.
Jacob is a Synthetic Chemist Associate at Avro. He holds a BSc in Medicinal Chemistry from the University of Waterloo, where he worked with the Taylor Research Group on the synthesis of calcium-dependent lipopeptide antibiotics. Jacob has years of experience in applying synthetic and analytical chemistry to support product development at pharmaceutical companies and start-ups.
Isabelle is a chemist at Avro, working on the design and synthesis of small molecules to be used for transdermal drug and nucleic acid delivery. She obtained her MSc in organic chemistry from York University while working on the enantioselective allylation of pyridines using palladium catalysis. Her research was funded by Hoffman La-Roche, giving her the opportunity to speak at a conference at Roche headquarters in Basel, Switzerland. She completed her BSc at the University of Toronto double majoring in Chemistry and Biochemistry. She also spent a semester playing hockey on an NCAA scholarship at the State University of New York Plattsburgh.